Evidence map›Paper›PMID 35636450›Full record

ArticleThrombosis and haemostasis2022

Autoimmune Acquired Factor XIII/13 Deficiency after SARS-CoV-2 mRNA Vaccination.

Shingen Nakamura, Motoki Sugasaki, Masayoshi Souri, Hirohito Akazawa, Maiko Sogawa, Taiki Hori, Hiroki Yamagami, Makoto Takishita, Ken-Ichi Aihara, Masahiro Abe and 3 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis and haemostasis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shingen NakamuraDepartment of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Motoki SugasakiDepartment of Medical Technology, Tokushima University Hospital, Tokushima, Japan.
Masayoshi SouriDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
Hirohito AkazawaDepartment of Dermatology, Anan Medical Center, Tokushima, Japan.
Maiko SogawaDepartment of Dermatology, Anan Medical Center, Tokushima, Japan.
Taiki HoriDepartment of Internal Medicine, Anan Medical Center, Tokushima, Japan.
Hiroki YamagamiDepartment of Internal Medicine, Anan Medical Center, Tokushima, Japan.
Makoto TakishitaDepartment of Internal Medicine, Anan Medical Center, Tokushima, Japan.
Ken-Ichi AiharaDepartment of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Masahiro AbeDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Atsushi YasumotoDivision of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Hokkaido, Japan.
Eriko MorishitaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Akitada IchinoseDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Factor XIII DeficiencyFactor XIIIHumansRNA, MessengerSARS-CoV-2VaccinationFactor XIIIRNA, Messenger

Identifiers

PMID35636450
PMCPMC9512586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.